Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Health Canada approves Strensiq for hypophosphatasia

Aug. 18, 2015

AVEO forms license agreement with Novartis for AV-380 and related antibodies

Aug. 18, 2015

Boehringer Ingelheim and Circuit Therapeutics collaborate on metabolic disorders

Aug. 14, 2015

LDL-cholesterol reductions observed in phase I study of CAT-2054

Aug. 14, 2015

Hua Medicine reports phase Ic data on HMS-5552 in type 2 diabetes

Aug. 14, 2015

Bioequivalence results announced for an agent for Fabry's disease

Aug. 14, 2015

KH-176 receives European orphan drug designation for MELAS syndrome

Aug. 14, 2015

Discovery and preclinical development of a MCH-R1 antagonist candidate for weight control

Aug. 13, 2015

IL-1alpha blockade shows promise for the treatment of type 2 diabetes

Aug. 12, 2015

FDA accepts La Jolla's IND for phase I study of LJPC-401

Aug. 12, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...